Skip to main content

The 2026 CCTG Plenary Session announces speakers

Friday April 24 | 4:30 - 5:30 pm
The 2025 CCTG Plenary Session announces speakers - Dr Chi Dr Nappi Dr Spreafico and Dr Chan

CCTG is pleased to announce the agenda for the The Plenary Session at the #CCT2026 Spring Meeting. 

The Plenary Session is on Friday April 24 4:30 - 5:30 in the Mountbatten Room at the Chelsea Hotel in Toronto. Each of the talks highlight important CCTG clinical trials and is a Royal College of Physicians and Surgeons of Canada accredited session. Thank you to this years CCTG Plenary Co-Chairs: Dr. Wendy Parulekar, Dr. Annette Hay, Dr. Wei Tu, and Dr. John Queenan.

Plan to stay after the Plenary to congratulate this years CCTG Recognition Award winners: 5:30-6:00 pm, Mountbatten Room at the Chelsea Hotel in Toronto

See the Annual Spring Meeting Schedule of Events for all meeting dates and times.

Dr Kim Chi 4:30 – 4:45 CCTG PR.21

PLUDO (Prostate Lutetium/Docetaxel): Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer & PSMA-Positive Disease

Dr. Chi is a medical oncologist and Professor in the Faculty of Medicine at the University of British Columbia and the Shrum Chair in Prostate Cancer Research at BC Cancer. His research in GU cancers focuses on prostate cancer and investigational new drugs, where he has contributed to changing international standards of care practice for patients with advanced prostate cancer.  He also has been investigating circulating tumour DNA as a source of prognostic and predictive biomarkers for patients with metastatic prostate cancer.


 

 

Dr. Nappi 4:45 – 5:00 CCTG GCC.1/SWOG S1823

Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly- Diagnosed Germ Cell Tumours

Dr. Nappi is a medical oncologist with the genitourinary group at BC Cancer in Vancouver, Assistant Professor in the Department of Urologic Sciences at the University of British Columbia, and senior research scientist at the Vancouver Prostate Centre. Her research focuses on the study of molecular mechanisms mediating resistance to the targeted and chemotherapy agents in GU tumours, drug discovery, and identification of new biomarkers for the diagnosis and treatment response/ resistance in patients with GU malignancies.

 

 

Dr. Spreafico5:00 – 5:15 CCTG HN.9 

Cisplatin + Radiotherapy (RT) vs Durvalumab + RT followed by Durvalumab vs Durvalumab + RT followed by Tremelimumab and Durvalumab in HPV-Positive Oropharyngeal Squamous Cell Cancer 

Dr. Spreafico is a medical oncologist and Clinician‑ Investigator at Princess Margaret Cancer Centre and Associate Professor of Medicine at the University of Toronto. She specializes in early‑ phase drug development with a focus on head and neck cancer and melanoma and leads multiple international investigator‑initiated trials integrating novel therapeutics with liquid biopsy and microbiome‑based biomarkers. She is actively engaged in education, leadership, and mentorship initiatives in CCTG, ASCO, ESMO and other international organizations.

 

 

Dr. Chan5:15 – 5:30 CCTG CO.21 CHALLENGE 

Impact of a Physical Activity Program on Disease-Free Survival in Patients with High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial - Economic Analysis

Dr. Chan is a medical oncologist at Sunnybrook Odette Cancer Centre, Associate Scientist at Sunnybrook Research Institute, and Professor at the University of Toronto. He is also Co-Director, Canadian Centre for Applied Research in Cancer Control. Dr. Chan’s research focuses on the different aspects of the value of cancer drugs, including health economics, health technology assessment, and real-world evidence. He is especially interested in cancer drug access, reimbursement, and cancer system sustainability